ProQuad Vaccine BLA Review Extended To September
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended its review of Merck's measles, mumps, rubella and varicella vaccine ProQuad by three months until Sept. 30
You may also be interested in...
Merck Proquad MMR/V Combo Vaccine Clears FDA With Approval For Second Round MMR Vaccination
The measles, mumps, rubella and varicella vaccine will be priced at $120.25 for an individual single-dose vial.
Merck Proquad MMR/V Combo Vaccine Clears FDA With Approval For Second Round MMR Vaccination
The measles, mumps, rubella and varicella vaccine will be priced at $120.25 for an individual single-dose vial.
Merck Vaccines Unit To Be Headed By U.S. Human Health President McGlynn
Margaret McGlynn will succeed Adel Mahmoud in overseeing four launches planned for 2005-2006, including HPV vaccine Gardasil.